Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018
First and only prostate cancer spacing device available for use in the U.S. clinically proven to preserve patient quality of life following radiation therapy
BEDFORD, Read more...
Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy Of Spaceoar Hydrogel In Patients Undergoing Dose-Escalated Stereotactic Body Radiation Therapy For Prostate Cancer
Application of SpaceOAR hydrogel significantly reduces rectal injury in a high-dose SBRT treated patient population
BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...
Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology
BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that Read more...
Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year
Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500
BEDFORD, Read more...
Sera Prognostics Receives Accreditation from College of American Pathologists
SALT LAKE CITY, June 29, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, announced today that the Accreditation Committee Read more...
Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel
The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy
June 28, 2017 03:14 PM Eastern Read more...
LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth
The PreTRM Test is the Only Validated Test That Provides Early and Individualized Evaluation of Preterm Birth Risk
BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® Read more...
Sera Prognostics Appoints Nadia Altomare as Chief Commercial Officer
SALT LAKE CITY, May 17, 2017– Sera Prognostics, Inc., a women’s healthcare company, announced today that Nadia F. Altomare has joined the company as Read more...
